Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
9 reports, 3 independent
Updated Sun 00:00
Mostly repetition
Reached 4 outlets in its first 24 hours
- Reports
- 9
- Developments
- 2
- Repetition
- 78%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Biovie submitted analyses to the FDA while listed on the Nasdaq exchange.1 source
BioVie announces CEO appointment, NASDAQ listing, and FDA review status for its drug candidate.1 source
Keep exploring
The entities involved
Related events
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Cardiol Therapeutics Inc. is listed on Nasdaq and is developing therapy for an FDA-approved indication.
- Alvotech utilized Nasdaq for its public stock listing and is currently undergoing comprehensive review by the FDA for biosimilar applications.
- Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.